PhaseBio is Drug Delivery in United States that focus on PhaseBio Pharmaceuticals Inc business. Founded in 2002. They cover business area such as PhaseBio Pharmaceuticals Inc, commercialization, novel therapy, orphan disease, an initial focus, cardiopulmonary indication, patient, major bleeding, urgent surgery, a fusion protein, pulmonary arterial hypertension, its preclinical product candidate, treatment-resistant hypertension.
2002
( 22 years old in 2024 )
PhaseBio Pharmaceuticals Inc
-
One Great Valley Parkway
Suite 30
Malvern, PA 19355
United States
Private
PhaseBio Pharmaceuticals Inccommercializationnovel therapyorphan diseasean initial focuscardiopulmonary indicationpatientmajor bleedingurgent surgerya fusion proteinpulmonary arterial hypertensionits preclinical product candidatetreatment-resistant hypertension
* We use standard office opening hours in near PhaseBio's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
PhaseBio is Drug Delivery business from United States that founded in 2002 (22 years old in 2024), PhaseBio business is focusing on PhaseBio Pharmaceuticals Inc.
PhaseBio headquarter office and corporate office address is located in One Great Valley Parkway Suite 30 Malvern, PA 19355 United States.
PhaseBio was founded in United States.
In 2024, PhaseBio is currently focus on PhaseBio Pharmaceuticals Inc sector.
Above is snippet of Google Trends for "PhaseBio Pharmaceuticals Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with PhaseBio, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
